Last reviewed · How we verify
Chemotherapy drug
Chemotherapy drugs work by damaging cancer cell DNA or disrupting cell division to kill rapidly dividing tumor cells.
Chemotherapy drugs work by damaging cancer cell DNA or disrupting cell division to kill rapidly dividing tumor cells. Used for Various solid tumors and hematologic malignancies (specific indication unknown).
At a glance
| Generic name | Chemotherapy drug |
|---|---|
| Also known as | Chemotherapy, carboplatin and pemetrexed, Systemic chemotherapy +/- targeted therapy, TP, oral fluoropyrimidine |
| Sponsor | University Hospital, Strasbourg, France |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Chemotherapy encompasses multiple drug classes with different mechanisms, including alkylating agents that cross-link DNA, antimetabolites that interfere with nucleotide synthesis, topoisomerase inhibitors that prevent DNA unwinding, and microtubule inhibitors that disrupt mitosis. The specific mechanism depends on the particular chemotherapy agent used.
Approved indications
- Various solid tumors and hematologic malignancies (specific indication unknown)
Common side effects
- Myelosuppression (neutropenia, anemia, thrombocytopenia)
- Nausea and vomiting
- Alopecia
- Mucositis
- Fatigue
- Diarrhea or constipation
Key clinical trials
- Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers (PHASE3)
- Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer (PHASE1)
- BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia (PHASE1)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- Hyperpolarized Imaging in Diagnosing Participants With Glioma (PHASE1)
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Chemotherapy drug CI brief — competitive landscape report
- Chemotherapy drug updates RSS · CI watch RSS
- University Hospital, Strasbourg, France portfolio CI